Glenmark Primes Complex Generics Play With Abraxane Copy Deal
Executive Summary
Glenmark has firmed up an alliance with Particle Sciences for a generic version of Celgene’s chemotherapy Abraxane as it shapes plans for a significant play in the complex generics space.
You may also be interested in...
Poland's Celon Pharma Pursues Innovation With Large Clinical Program Starting Next Year
Following one of the largest initial public offerings this year in Poland, Celon Pharma is pioneering the development of innovative pharmaceuticals in the East European country, including novel anti-inflammatory, neuropsychiatric and oncology products.
Seretide Competition Builds Up But Substitutability Holds Key?
More possible competition is building for GlaxoSmithKline's blockbuster salmeterol and fluticasone combination, with a second Indian firm teaming up with the Polish biopharmaceutical company Celon to produce a version of the product.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.